参考文献/References:
[1] Krajewski W,Wojciechowska J,Dembowski J,et al. Hydronephrosis in the course of ureteropelvic junction obstruction:an underestimated problem? Current opinions on the pathogenesis,diagnosis and treatment[J]. Adv Clin Exp Med,2017,26(5):857-864.
[2] Textor SC,Lerman L. Renovascular hypertension and ischemic nephropathy[J]. Am J Hypertens,2010,23(11):1159-1169.
[3] de Mast Q,Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups:a systematic literature review[J].J Hypertens,2009,27(7):1333-1340.
[4] Meena DS,Kumar D,Bohra GK,et al. A 37-year-old male with unilateral hydronephrosis:a forgotten cause of secondary hypertension[J]. J Family Med Prim Care,2020,9(2):1219-1221.
[5] Podevin G,Mandelbrot L,Vuillard E,et al.Outcome of urological abnormalities prenatally diagnosed by ultrasound[J]. Fetal Diagn Ther,1996,11(3):181-190.
[6] Mallik M,Watson AR. Antenatally detected urinary tract abnormalities:more
detection but less action[J]. Pediatr Nephrol,2008,23(6):897-904.
[7] Woodward M,Frank D. Postnatal management of antenatal hydronephrosis[J].BJU Int,2002,89(2):149-156.
[8] Gulati R,Verdin H,Halanaik D,et al. Co-occurrence of congenital hydronephrosis and FOXL2-associated blepharophimosis,ptosis,epicanthus inversus syndrome(BPES)[J]. Eur J Med Genet,2014,57(10):576-578.
[9] Patel K,Batura D. An overview of hydronephrosis in adults[J]. Br J Hosp Med(Lond),2020,81(1):1-8.
[10] Wanner C,Luscher TF,Schollmeyer P,et al. Unilateral hydronephrosis and hypertension:cause or coincidence[J]? Nephron,1987,45(3):236-241.
[11] Kawano S,Yano S,Takahashi S,et al. A case of hypertension due to unilateral hydronephrosis in a child[J]. Eur Urol,1986,12(5):357-359.
[12] Chevalier RL. Molecular and cellular pathophysiology of obstructive nephropathy[J]. Pediatr Nephrol,1999,13(7):612-619.
[13] Peleli M,Al-Mashhadi A,Yang T,et al. Renal denervation attenuates NADPH oxidase-mediated oxidative stress and hypertension in rats with hydronephrosis[J]. Am J Physiol Renal Physiol,2016,310(1):F43-F56.
[14] Carlstrom M,Sallstrom J,Skott O,et al. Hydronephrosis causes salt-sensitive hypertension and impaired renal concentrating ability in mice[J]. Acta Physiol(Oxf),2007,189(3):293-301.
[15] Tauchi K,Kanehara H. Hypertension and the renin-angiotensin system in the congenital hydronephrosis rat with non-obstructive pelviureteric junction abnormalities[J]. Exp Nephrol,1996,4(1):60-64.
[16] Topcu SO,Pedersen M,Norregaard R,et al. Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction[J]. Am J Physiol Renal Physiol,2007,292(2):F736-F748.
[17] Zhang Y,Ma L,Wu J,et al. Hydronephrosis alters cardiac ACE2 and Mas receptor expression in mice[J]. J Renin Angiotensin Aldosterone Syst,2015,16(2):267-274.
[18] Watanabe M,Nishikawa T,Takagi T,et al. Mechanism of suppressed renin-angiotensin system in spontaneously hypertensive rat(SHR)[J]. Clin Exp Hypertens A,1983,5(1):49-70.
[19] Majid DS,Kopkan L. Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension[J]. Clin Exp Pharmacol Physiol,2007,34(9):46-52.
[20] DiBona GF. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function[J]. Hypertension,2000, 36(6):1083-1088.
[21] Arnold AC,Shaltout HA,Gilliam-Davis S,et al. Autonomic control of the heart is altered in Sprague-Dawley rats with spontaneous hydronephrosis[J]. Am J Physiol Heart Circ Physiol,2011,300(6):H2206-H2213.
[22] Dibona GF,Kopp UC. Neural control of renal function[J]. Physiol Rev,1997,77(1):75-197.
[23] Carlstrom M,Wilcox CS,Arendshorst WJ. Renal autoregulation in health and disease[J]. Physiol Rev,2015,95(2):405-511.
[24] Drummond GR,Selemidis S,Griendling KK,et al. Combating oxidative stress in vascular disease:NADPH oxidases as therapeutic targets[J]. Nat Rev Drug Discov,2011,10(6):453-471.
[25] Singh D,Kaur R,Chander V,et al. Antioxidants in the prevention of renal disease[J]. J Med Food,2006,9(4):443-450.
[26] Kawada N,Moriyama T,Ando A,et al.Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction[J].Kidney Int,1999,56(3):1004-1013.
[27] Wilcox CS. Redox regulation of the afferent arteriole and tubuloglomerular feedback[J]. Acta Physiol Scand,2010,179(3):217-223.
[28] Haidara MA,Yassin HZ,Rateb M,et al. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus[J]. Curr Vasc Pharmacol,2006,4(3):215-227.
[29] Moriyama T,Kawada N,Nagatoya K,et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction[J]. Kidney Int,2001,59(6):2095-2103.
[30] Carlstr?m M,Brown RD,S?llstr?m J,et al. SOD1-deficiency causes salt-sensitivity and aggravates hypertension in hydronephrosis[J]. Am J Physiol Regul Integr Comp Physiol,2009,297(1):R82-R92.
[31] Palloshi A,Fragasso G,Piatti P,et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension,positive exercise tests,and normal coronary arteries[J]. Am J C ardiol,2004,93(7):933-935.
[32] Schramm L,La M,Heidbreder E,et al. L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation[J]. Kidney Int,2002,61(4):1423-1432.
[33] Carlstr?m M,Brown RD,Edlund J,et al. Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals[J]. Am J Physiol Renal Physiol,2008,294(2):F362-F370.
[34] Carlstrom M,Lai EY,Steege A,et al. Nitric oxide deficiency and increased adenosine response of afferent arterioles in hydronephrotic mice with hypertension[J]. Hypertension,2008,51(5):1386-1392.
[35] Li WQ,Dong ZQ,Zhou XB,et al. Renovascular morphological changes in a rabbit model of hydronephrosis[J]. J Huazhong Univ Sci Technolog Med Sci,2014,34(4):575-581.
[36] 黄倩,柳懿鹏. 不同程度肾积水家兔模型在不同压力肾盂灌注下的肾损伤[J]. 中国医科大学学报,2019,48(12):1085-1090.
[37] Yao X,Cheng F,Yu W,et al. Kidney fibrosis induced by various irrigation pressures in mouse models of mild and severe hydronephrosis[J]. Int Urol Nephrol,2019,51(2):215-222.
[38] Sinha A ,Bagga A,Krishna A,et al. Revised guidelines on management of antenatal hydronephrosis[J]. Indian J Nephrol,2013,23(2):83-97.
[39] Kohno M,Ogawa T,Kojima Y,et al. Pediatric congenital hydronephrosis(ureteropelvic junction obstruction):medical management guide[J]. Int J Urol,2020,27(5):369-376.
[40] Areses Trapote R,Urbieta Garagorri MA,Ubetagoyena Arrieta M,et al. Severe primary congenital unilateral hydronephrosis. A review of 98 cases[J]. An Pediatr(Barc),2006,64(1):11-20.
[41] Al-Mashhadi A,Neveus T,Stenberg A,et al.Surgical treatment reduces blood pressure in children with unilateral congenital hydronephrosis[J]. J Pediatr Urol,2015,11(91):e91-e96.
[42] Al-Mashhadi A,H?ggman M,L?ckgren G,et al. Changes of arterial pressure following relief of obstruction in adults with hydronephrosis[J].Ups J Med Sci,2018,123(4):216-224.
[43] de Waard D,Dik P,Lilien MR,et al. Hypertension is an indication for surgery in children with ureteropelvic junction obstruction[J]. J Urol,2008,179(5):1976-1978.
[44] Al-Mashhadi A,Checa A,Wahlin N,et al. Changes in arterial pressure and markers of nitric oxide homeostasis and oxidative stress following surgical correction of hydronephrosis in children[J]. Pediatr Nephrol,2018,33(4):639-649.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(3):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]